CTI grew from a Cincinnati startup to a global leader in clinical research. CEO Tim Schroder shares insights on its success ...

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing ...

| Discover how AI and RWD are transforming drug development by optimizing clinical trial protocols, enhancing recruitment, ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...